Infinity Pharmaceuticals Inc
OTC:INFIQ

Watchlist Manager
Infinity Pharmaceuticals Inc Logo
Infinity Pharmaceuticals Inc
OTC:INFIQ
Watchlist
Price: 0.0001 USD Market Closed
Market Cap: 91 USD
Have any thoughts about
Infinity Pharmaceuticals Inc?
Write Note

Infinity Pharmaceuticals Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Infinity Pharmaceuticals Inc
Income from Continuing Operations Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Infinity Pharmaceuticals Inc
OTC:INFIQ
Income from Continuing Operations
-$40.9m
CAGR 3-Years
2%
CAGR 5-Years
N/A
CAGR 10-Years
7%
Abbvie Inc
NYSE:ABBV
Income from Continuing Operations
$5.4B
CAGR 3-Years
-7%
CAGR 5-Years
5%
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Income from Continuing Operations
$1B
CAGR 3-Years
-41%
CAGR 5-Years
-30%
CAGR 10-Years
-18%
Amgen Inc
NASDAQ:AMGN
Income from Continuing Operations
$3.1B
CAGR 3-Years
-18%
CAGR 5-Years
-17%
CAGR 10-Years
-5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Income from Continuing Operations
-$489.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
1%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Income from Continuing Operations
$4.3B
CAGR 3-Years
-11%
CAGR 5-Years
17%
CAGR 10-Years
27%

See Also

What is Infinity Pharmaceuticals Inc's Income from Continuing Operations?
Income from Continuing Operations
-40.9m USD

Based on the financial report for Jun 30, 2023, Infinity Pharmaceuticals Inc's Income from Continuing Operations amounts to -40.9m USD.

What is Infinity Pharmaceuticals Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
7%

Over the last year, the Income from Continuing Operations growth was 13%. The average annual Income from Continuing Operations growth rates for Infinity Pharmaceuticals Inc have been 2% over the past three years , and 7% over the past ten years .

Back to Top